Match!
Amy Claxton
Alkermes
PsychiatryPsychologyInsulinDiabetes mellitusClinical psychology
31Publications
10H-index
1,377Citations
What is this?
Publications 31
Newest
#1Henry A. NasrallahH-Index: 59
#2Ralph AquilaH-Index: 7
Last. Peter J. WeidenH-Index: 43
view all 6 authors...
1 CitationsSource
#1Michael E. Thase (UPenn: University of Pennsylvania)H-Index: 113
#2Arielle D. Stanford (Alkermes)H-Index: 14
Last. Sanjeev Pathak (Alkermes)H-Index: 2
view all 10 authors...
Buprenorphine/samidorphan (BUP/SAM; ALKS 5461) is an investigational opioid system modulator for the adjunctive treatment of patients with major depressive disorder (MDD), who did not respond adequately to prior antidepressant therapy (ADT). FORWARD-2, an open-label extension study, assessed long-term safety and tolerability of adjunctive BUP/SAM treatment in these patients. Patients from four short-term trials and de novo patients were enrolled; all had confirmed MDD and a current major depress...
1 CitationsSource
#1Suzanne CraftH-Index: 77
#2Amy ClaxtonH-Index: 10
Last. Philip ZeitlerH-Index: 30
view all 12 authors...
Insulin resistance and impaired β-cell function are associated with risk of cognitive decline in adults over 65 y of age. Their impact on cognition in youth and adults 25 mmol/L. The cognitive battery (CogState TM and story recall) assessed 1) psychomotor speed; 2) visual pattern separation; 3) visual attention and working memory; and 4) verbal learning and episodic memory. Linear regression models were fit to assess relationships between cognition and clamp measures by age group, adjusted for a...
Source
#1Brian J. MillerH-Index: 27
#2Amy Claxton (Alkermes)H-Index: 10
Last. Steven G. Potkin (UCI: University of California, Irvine)H-Index: 83
view all 5 authors...
Abstract We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients ( n = 50 PP; n = 1 RLAI) enrolled; 35 completed ...
Source
#1Alessio FasanoH-Index: 85
#2Amy ClaxtonH-Index: 10
view all 5 authors...
Source
#1Alessio Fasano (UMB: University of Maryland, Baltimore)H-Index: 85
#2Amy Claxton (Alkermes)H-Index: 10
Last. Yangchun Du (Alkermes)
view all 4 authors...
Source
#1Christoph U. Correll (Albert Einstein College of Medicine)H-Index: 29
#2Arielle D. Stanford (Alkermes)H-Index: 14
Last. Peter J. Weiden (Alkermes)H-Index: 43
view all 5 authors...
Abstract To assess the effect of the long-acting antipsychotic aripiprazole lauroxil (AL) on social and functional outcomes compared with placebo in patients with acute schizophrenia, a post-hoc analysis was conducted. Patients with acute schizophrenia were enrolled in a 12-week, double-blind, placebo-controlled efficacy trial, and randomized 1:1:1 to receive AL 441 mg, AL 882 mg, or placebo every 4 weeks. Changes in social functioning using the 6- and 4-item Positive and Negative Syndrome Scale...
Source
#1Michael E. Thase (UPenn: University of Pennsylvania)H-Index: 113
#2Arielle D. Stanford (Alkermes)H-Index: 14
Last. Sanjeev Pathak (Alkermes)H-Index: 2
view all 9 authors...
Source
#1Peter J. WeidenH-Index: 43
#2Amy ClaxtonH-Index: 10
Last. John LaurielloH-Index: 39
view all 4 authors...
Source
#1Suzanne Craft (Wake Forest University)H-Index: 77
#2Amy Claxton (Alkermes)H-Index: 10
Last. Seth D. Friedman (Seattle Children's)H-Index: 37
view all 14 authors...
65 CitationsSource
1234